{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:50:46Z","timestamp":1760147446947,"version":"3.41.0"},"reference-count":66,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the<ns4:italic>TSC1<\/ns4:italic>or<ns4:italic>TSC2<\/ns4:italic>genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.<\/ns4:p>","DOI":"10.12688\/f1000research.11110.1","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T13:15:07Z","timestamp":1497014107000},"page":"859","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)"],"prefix":"10.12688","volume":"6","author":[{"given":"Tanjala T.","family":"Gipson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-6028","authenticated-orcid":false,"given":"Michael V.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1-8","DOI":"10.2147\/TACG.S90262","article-title":"Genetics of tuberous sclerosis complex: implications for clinical practice.","volume":"10","author":"C Caban","year":"2016","journal-title":"Appl Clin Genet."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"67-75","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease.","volume":"33","author":"C Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"112-53","DOI":"10.1016\/j.neuroscience.2016.11.017","article-title":"Molecular neurobiology of mTOR.","volume":"341","author":"K Switon","year":"2017","journal-title":"Neuroscience."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"379-92","DOI":"10.1038\/nrneurol.2016.81","article-title":"The mTOR signalling cascade: paving new roads to cure neurological disease.","volume":"12","author":"P Crino","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"243-54","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.","volume":"49","author":"H Northrup","year":"2013","journal-title":"Pediatr Neurol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"17-23","DOI":"10.1111\/j.1528-1167.2005.00353.x","article-title":"Neurocutaneous syndromes and epilepsy-issues in diagnosis and management.","volume":"46 Suppl 10","author":"J Cross","year":"2005","journal-title":"Epilepsia."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"318-25","DOI":"10.1177\/08830738050200040901","article-title":"Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment.","volume":"20","author":"P Curatolo","year":"2005","journal-title":"J Child Neurol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"203-9","DOI":"10.1111\/j.1469-8749.1990.tb16926.x","article-title":"Tuberous sclerosis and infantile spasms.","volume":"32","author":"R Riikonen","year":"1990","journal-title":"Dev Med Child Neurol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"766-74","DOI":"10.1111\/j.1469-8749.1992.tb11515.x","article-title":"Seizures and intellectual disability associated with tuberous sclerosis complex in the west of Scotland.","volume":"34","author":"C Shepherd","year":"1992","journal-title":"Dev Med Child Neurol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1236-41","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex.","volume":"51","author":"C Chu-Shore","year":"2010","journal-title":"Epilepsia."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1059-71","DOI":"10.1093\/cercor\/bhu276","article-title":"Cortical Tubers: Windows into Dysregulation of Epilepsy Risk and Synaptic Signaling Genes by MicroRNAs.","volume":"26","author":"A Dombkowski","year":"2016","journal-title":"Cereb Cortex."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"41-51","DOI":"10.1111\/j.1365-2788.1993.tb00868.x","article-title":"Development, behaviour and seizures in 300 cases of tuberous sclerosis.","volume":"37","author":"A Hunt","year":"1993","journal-title":"J Intellect Disabil Res."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"335-44","DOI":"10.1017\/S0033291702007092","article-title":"Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex.","volume":"33","author":"C Joinson","year":"2003","journal-title":"Psychol Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"916-23","DOI":"10.1212\/01.wnl.0000280579.04974.c0","article-title":"Cognitive impairment in tuberous sclerosis complex is a multifactorial condition.","volume":"70","author":"F Jansen","year":"2008","journal-title":"Neurology."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"22-7","DOI":"10.1111\/j.1528-1167.2010.02892.x","article-title":"Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex.","volume":"52","author":"M Kaczorowska","year":"2011","journal-title":"Epilepsia."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2321-31","DOI":"10.1017\/S0033291715000264","article-title":"Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study.","volume":"45","author":"P Bolton","year":"2015","journal-title":"Psychol Med."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"815-22","DOI":"10.1136\/jmedgenet-2015-103154","article-title":"Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins.","volume":"52","author":"H Wong","year":"2015","journal-title":"J Med Genet."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"161-7","DOI":"10.1007\/s00415-016-8335-5","article-title":"Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex.","volume":"264","author":"I Overwater","year":"2017","journal-title":"J Neurol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1871-6","DOI":"10.1177\/0883073815600871","article-title":"Autism Phenotypes in Tuberous Sclerosis Complex: Diagnostic and Treatment Considerations.","volume":"30","author":"T Gipson","year":"2015","journal-title":"J Child Neurol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13023-015-0371-1","article-title":"Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers.","volume":"10","author":"A Vignoli","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"766-72","DOI":"10.1212\/WNL.0000000000003002","article-title":"Symptom profiles of autism spectrum disorder in tuberous sclerosis complex.","volume":"87","author":"S Jeste","year":"2016","journal-title":"Neurology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fnins.2015.00420","article-title":"Autism spectrum disorders and neuropathology of the cerebellum.","volume":"9","author":"D Hampson","year":"2015","journal-title":"Front Neurosci."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"50-6","DOI":"10.1111\/j.1469-8749.1994.tb11765.x","article-title":"Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study.","volume":"36","author":"I Gillberg","year":"1994","journal-title":"Dev Med Child Neurol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"323-39","DOI":"10.1007\/BF01046223","article-title":"A prevalence study of autism in tuberous sclerosis.","volume":"23","author":"A Hunt","year":"1993","journal-title":"J Autism Dev Disord."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"698-705","DOI":"10.1111\/j.1469-8749.1991.tb14947.x","article-title":"Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings.","volume":"33","author":"I Jambaqu\u00e9","year":"1991","journal-title":"Dev Med Child Neurol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"339-55","DOI":"10.1007\/bf01048239","article-title":"Autism and tuberous sclerosis.","volume":"22","author":"S Smalley","year":"1992","journal-title":"J Autism Dev Disord."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"279-85","DOI":"10.1023\/A:1026004501631","article-title":"Autism and tuberous sclerosis complex: prevalence and clinical features.","volume":"28","author":"P Baker","year":"1998","journal-title":"J Autism Dev Disord."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"97-103","DOI":"10.1023\/A:1026032413811","article-title":"Autism in tuberous sclerosis complex.","volume":"28","author":"G Gutierrez","year":"1998","journal-title":"J Autism Dev Disord."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"520-5","DOI":"10.1177\/0883073807309788","article-title":"Characterization of autism in young children with tuberous sclerosis complex.","volume":"23","author":"S Jeste","year":"2008","journal-title":"J Child Neurol."},{"key":"ref-30","first-page":"374-379","article-title":"[Autism in tuberous sclerosis].","volume":"130","author":"R Calder\u00f3n Gonz\u00e1lez","year":"1994","journal-title":"Gac Med Mex."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"981-7","DOI":"10.1212\/WNL.0b013e3182104347","article-title":"Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex.","volume":"76","author":"A Numis","year":"2011","journal-title":"Neurology."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"392-5","DOI":"10.1016\/S0140-6736(97)80012-8","article-title":"Association of tuberous sclerosis of temporal lobes with autism and atypical autism.","volume":"349","author":"P Bolton","year":"1997","journal-title":"Lancet."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"262-6","DOI":"10.1016\/j.yebeh.2010.04.010","article-title":"The clinical utility of the Social Responsiveness Scale and Social Communication Questionnaire in tuberous sclerosis complex.","volume":"18","author":"Y Granader","year":"2010","journal-title":"Epilepsy Behav."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"25-35","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist.","volume":"52","author":"P de Vries","year":"2015","journal-title":"Pediatr Neurol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1181-92","DOI":"10.1586\/era.11.93","article-title":"Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.","volume":"11","author":"D Franz","year":"2011","journal-title":"Expert Rev Anticancer Ther."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"51-60","DOI":"10.2165\/11207730-000000000-00000","article-title":"Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.","volume":"14","author":"M Curran","year":"2012","journal-title":"Paediatr Drugs."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"817-24","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"381","author":"J Bissler","year":"2013","journal-title":"Lancet."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1595-606","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis.","volume":"364","author":"F McCormack","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"539-51","DOI":"10.1002\/ana.22696","article-title":"Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.","volume":"71","author":"D Talos","year":"2012","journal-title":"Ann Neurol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"e57445","DOI":"10.1371\/journal.pone.0057445","article-title":"Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.","volume":"8","author":"B Zhang","year":"2013","journal-title":"PLoS One."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1270-4","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.","volume":"38","author":"F Vigevano","year":"1997","journal-title":"Epilepsia."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"15-9","DOI":"10.1016\/j.yebeh.2015.12.004","article-title":"Sabril\u00ae registry 5-year results: Characteristics of adult patients treated with vigabatrin.","volume":"56","author":"G Krauss","year":"2016","journal-title":"Epilepsy Behav."},{"key":"ref-43","doi-asserted-by":"crossref","first-page":"353-412","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007.","volume":"9","author":"J Wheless","year":"2007","journal-title":"Epileptic Disord."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"2408-15","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis.","volume":"87","author":"D Krueger","year":"2016","journal-title":"Neurology."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.","volume":"11","author":"S Samueli","year":"2016","journal-title":"Orphanet J Rare Dis."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"2153-63","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.","volume":"388","author":"J French","year":"2016","journal-title":"Lancet."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"16-24","DOI":"10.1007\/s00787-006-0570-3","article-title":"The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families.","volume":"16","author":"P de Vries","year":"2007","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"733-45","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex.","volume":"14","author":"P Curatolo","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"873-80","DOI":"10.1177\/0883073810361789","article-title":"Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment.","volume":"25","author":"P Curatolo","year":"2010","journal-title":"J Child Neurol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1866-1955-6-10","article-title":"Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers.","volume":"6","author":"K Eden","year":"2014","journal-title":"J Neurodev Disord."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1247-55","DOI":"10.1093\/brain\/awf124","article-title":"Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.","volume":"125","author":"P Bolton","year":"2002","journal-title":"Brain."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"203-7","DOI":"10.1136\/jmg.2003.012757","article-title":"Genotype and psychological phenotype in tuberous sclerosis.","volume":"41","author":"J Lewis","year":"2004","journal-title":"J Med Genet."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"561-9","DOI":"10.1111\/j.1365-2788.2006.00828.x","article-title":"Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis.","volume":"50","author":"A Raznahan","year":"2006","journal-title":"J Intellect Disabil Res."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"506-13","DOI":"10.1016\/j.yebeh.2007.07.010","article-title":"Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex.","volume":"11","author":"D Muzykewicz","year":"2007","journal-title":"Epilepsy Behav."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"261-71","DOI":"10.1093\/cercor\/bhj144","article-title":"Neuroanatomical correlates of memory deficits in tuberous sclerosis complex.","volume":"17","author":"K Ridler","year":"2007","journal-title":"Cereb Cortex."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"387-95","DOI":"10.1002\/ajmg.a.32690","article-title":"Neuropsychological attention deficits in tuberous sclerosis complex (TSC).","volume":"149A","author":"P de Vries","year":"2009","journal-title":"Am J Med Genet A."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"387-396","DOI":"10.1002\/9783527630073.ch19","article-title":"Impact of TSC on the family and genetic counseling issues.","author":"V Whittemore","year":"2010"},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"4071-81","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.","volume":"17","author":"D Davies","year":"2011","journal-title":"Clin Cancer Res."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"2165-72","DOI":"10.2147\/NDT.S91248","article-title":"Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.","volume":"12","author":"J Capal","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"122-5","DOI":"10.1016\/j.ebcr.2013.06.004","article-title":"Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior.","volume":"1","author":"T Gipson","year":"2013","journal-title":"Epilepsy Behav Case Rep."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"424-31","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.","volume":"15","author":"S J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1632; author reply 1632-4","DOI":"10.1111\/j.1528-1167.2007.01178_3.x","article-title":"Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex.","volume":"48","author":"S J\u00f3zwiak","year":"2007","journal-title":"Epilepsia."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"29-34","DOI":"10.1016\/j.pediatrneurol.2015.09.013","article-title":"Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants.","volume":"54","author":"J Wu","year":"2016","journal-title":"Pediatr Neurol."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"108-16","DOI":"10.1111\/epi.12484","article-title":"Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis.","volume":"55","author":"A Humphrey","year":"2014","journal-title":"Epilepsia."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"33-42","DOI":"10.1016\/S1474-4422(16)30294-0","article-title":"Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.","volume":"16","author":"F O\u2019 Callaghan","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"81-6","DOI":"10.1016\/j.seizure.2016.11.021","article-title":"Epileptic spasms - 175 years on: Trying to teach an old dog new tricks.","volume":"44","author":"J Wilmshurst","year":"2017","journal-title":"Seizure."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-859\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-859\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-859\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:42:40Z","timestamp":1750300960000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-859\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":66,"URL":"https:\/\/doi.org\/10.12688\/f1000research.11110.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.11986.r22796","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11986.r22797","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11986.r22798","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"type":"electronic","value":"2046-1402"}],"subject":[],"published":{"date-parts":[[2017,6,9]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-859\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.11986.r22797, Paolo Curatolo, Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, Rome, Italy, 09 Jun 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-859\/v1#referee-response-22797","order":0,"name":"referee-response-22797","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11986.r22796, Peter Crino, Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA, 09 Jun 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-859\/v1#referee-response-22796","order":1,"name":"referee-response-22796","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11986.r22798, Mustafa Sahin, Department of Neurology, F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, 09 Jun 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-859\/v1#referee-response-22798","order":2,"name":"referee-response-22798","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}